

66 (1) (2)

45

31

21

14

6.5

Fig. 1A

66 (1) (2) (3) (4)

45

31

21

14

6.5

Fig. 1B




Fig. 1C

Salivary IgA anti-SBR (specific / total x 100)




Fig. 2A

Vaginal IgA anti-SBR (specific / total x 100)




Fig. 2B




Fig. 3A




Fig. 3B





Fig. 3C

Saliva IgA anti-holotoxin (specific / total x 100)




Immunogen/ Group

☐ SBR-CTA2/B

▨ SBR-LT-IIaA2/B

Fig. 4A

Vaginal IgA anti-holotoxin (specific / total x 100)



Immunogen/Group

☐ SBR-CTA2/B

▨ SBR-LT-IIaA2/B

Fig. 4B

Immunogen/Group

▨ SBR-CTA2/B

▩ SBR-LT-IIaA2/B




Fig. 4C

Immunogen/Group

▨ SBR-CTA2/B

▩ SBR-LT-IIaA2/B




Fig. 4D




Fig. 5A

B cell treatment:




Fig. 5B




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6D






Fig. 6E






Fig. 7

**Ab Treatment:**




**Fig. 8A**


**Ab Treatment:**



**Fig. 8B**

[illegible]

**Fig. 8C**



**Fig. 8D**